Rain Therapeutics Ownership

Summary

RAINDelisted Stock

USD 1.41 0.01 0.70%

Rain Therapeutics owns a total of 27.58 Million outstanding shares. Over half of Rain Therapeutics' outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.

Some institutional investors establish a significant position in stocks such as Rain Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Rain Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

Rain Stock Ownership Analysis

About 16.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.65. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Rain Therapeutics recorded a loss per share of 2.07. The entity had not issued any dividends in recent years. Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California. Rain Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 44 people. To find out more about Rain Therapeutics contact Avanish MBA at 510 953 5559 or learn more at https://www.rainoncology.com.

Rain Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Rain Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Rain Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Rain Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

		Doebele Robert over six months ago Disposition pursuant to a tender of shares in a change of control transaction by Doebele Robert of Rain Therapeutics
		Tang Kevin C over a year ago Purchase by Tang Kevin C of 74812 shares of Rain Therapeutics
		Nelson Cabatuan over a year ago Acquisition by Nelson Cabatuan of 65325 shares of Rain Therapeutics subject to Rule 16b-3

Rain Therapeutics Outstanding Bonds

Rain Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Rain Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Rain bonds can be classified according to their maturity, which is the date when Rain Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

	Dana 575 percent Corp Bond US235822AB96	View
	Volcan Compania Minera Corp Bond USP98047AC08	View
	Boeing Co 2196 Corp Bond US097023DG73	View
	HSBC Holdings PLC Corp Bond US404280DR76	View
	MPLX LP 52 Corp Bond US55336VAL45	View
	International Game Technology Corp Bond US460599AD57	View
	Morgan Stanley 3591 Corp Bond US61744YAK47	View
	MGM Resorts International Corp Bond US552953CD18	View

View All Rain Therapeutics Corporate Bonds

Pair Trading with Rain Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Rain Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rain Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Rain Stock

0.79	BKRKY	Bank Rakyat	Pair Corr
0.73	BKRKF	PT Bank Rakyat	Pair Corr
0.7	PPERY	Bank Mandiri Persero	Pair Corr
0.65	PPERF	Bank Mandiri Persero	Pair Corr

Moving against Rain Stock

0.98	SSNLF	Samsung Electronics	Pair Corr
0.78	XOM	Exxon Mobil Corp Sell-off Trend	Pair Corr
0.77	CSCO	Cisco Systems Aggressive Push	Pair Corr
0.77	AA	Alcoa Corp Fiscal Year End 15th of January 2025	Pair Corr
0.72	CAT	Caterpillar Fiscal Year End 3rd of February 2025	Pair Corr

The ability to find closely correlated positions to Rain Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Rain Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Rain Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Rain Therapeutics to buy it.

The correlation of Rain Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Rain Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Rain Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Rain Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Other Consideration for investing in Rain Stock

If you are still planning to invest in Rain Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Rain Therapeutics' history and understand the potential risks before investing.

	Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
	Insider Screener Find insiders across different sectors to evaluate their impact on performance
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated
	Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC